



List of original scientific publications of clinical trials of cooperative groups for the past three years

GETUG 2019
<p>GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol. Pasquier D, Le Deley MC, Tresch E, Cormier L, Duterque M, Nenan S, Lartigau E. BMJ Open. 2019 Aug 2;9(8):e026666. doi: 10.1136/bmjopen-2018-026666.</p>
<p>Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.</p> <p>Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16.PMID: 31629656</p>
<p>Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houédé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.PMID: 31194611 Clinical Trial.</p>
<p>Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Guillot A, Joly C, Barthélémy P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K. Clin Genitourin Cancer. 2019 Feb;17(1):e38-e43. doi: 10.1016/j.clgc.2018.08.006. Epub 2018 Sep 6.PMID: 30279115</p>
GETUG 2020
<p>Nivoren (GETUG AFU 26):Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.</p>

Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, Fahrner JE, Le Chatellier E, Pons N, Galleron N, Roume H, Duong CPM, Mondragón L, Iribarren K, Bonvalet M, Terrisse S, Rauber C, Goubet AG, Daillère R, Lemaitre F, Reni A, Casu B, Alou MT, Alves Costa Silva C, Raoult D, Fizazi K, Escudier B, Kroemer G, Albiges L, Zitvogel L. **Eur Urol.** **2020 Aug**;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4.

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (**GETUG-AFU 17**): a randomised, phase 3 trial. Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P. **Lancet Oncol.** **2020 Oct**;21(10):1341-1352. doi: 10.1016/S1470-2045(20)30454-X.PMID: 33002438 Clinical Trial.

Re: Adjuvant Radiotherapy Versus Early Salvage Radiotherapy plus Short-term Androgen Deprivation Therapy in Men with Localised Prostate Cancer After Radical Prostatectomy (**GETUG-AFU 17**): A Randomised, Phase 3 Trial. Rodríguez-Sánchez L, Crehange G, Bennamoun M, Macek P, Cathelineau X, Sanchez-Salas R. **Eur Urol.** **2020 Dec** 2:S0302-2838(20)30933-7. doi: 10.1016/j.eururo.2020.11.032. Online ahead of print.PMID: 33279305

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF; **ARTISTIC Meta-analysis Group.** **Lancet.** **2020 Oct** 31;396(10260):1422-1431. doi: 10.1016/S0140-6736(20)31952-8. Epub 2020 Sep 28.PMID: 33002431

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER **GETUG-12 Trial**. Dumont C, Baciarello G, Bosset PO, Lavaud P, Colomba E, Massard C, Lorient Y, Albiges L, Blanchard P, Bossi A, Nenan S, Fizazi K. **Clin Genitourin Cancer.** **2020 Dec**;18(6):444-451. doi: 10.1016/j.clgc.2020.03.017. Epub 2020 Apr 7.PMID: 32349927

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; **VESPER Trial Investigators.** **Contemp Clin Trials Commun.** **2020 Jan** 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar.PMID: 32083220 Free PMC article.

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the **GETUG/AFU V05 VESPER Trial** Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; **VESPER Trial Investigators.** **Eur Urol.** **2020 Aug** 28:S0302-2838(20)30641-2. doi: 10.1016/j.eururo.2020.08.024. Online ahead of print.PMID: 32868138

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II **AXIPAP** trial. Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, Chevreau C, Boyle H, Rolland F, Blanc E, Ravaud A, Dermeche S, Flechon A, Albiges L, Pérol D, Escudier B; GETUG collaborative group. **Eur J Cancer.** 2020 Apr;129:107-116. doi: 10.1016/j.ejca.2020.02.001. Epub 2020 Mar 5. PMID: 32146304 Clinical Trial.

GETUG 2021

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the **GETUG/AFU V05 VESPER** Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S; VESPER Trial Investigators. **Eur Urol.** 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28.

OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Morvan C, Campion L, Blanc-Lapierre A. **Eur Urol.** 2021 Oct;80(4):405-414. doi: 10.1016/j.eururo.2021.06.010. Epub 2021 Jul 8. PMID: 34247896

Re: Adjuvant Radiotherapy Versus Early Salvage Radiotherapy plus Short-term Androgen Deprivation Therapy in Men with Localised Prostate Cancer After Radical Prostatectomy (**GETUG-AFU 17**): A Randomised, Phase 3 Trial. Rodríguez-Sánchez L, Crehange G, Bennamoun M, Macek P, Cathelineau X, Sanchez-Salas R. **Eur Urol.** 2021 Apr;79(4):555-556. doi: 10.1016/j.eururo.2020.11.032. Epub 2020 Dec 2.

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the **GETUG-AFU 26 NIVOREN** Trial. Courcier J, Dalban C, Laguerre B, Ladoire S, Barthélémy P, Oudard S, Joly F, Gravis G, Chevreau C, Geoffrois L, Deluche É, Rolland F, Topart D, Culine S, Négrier S, Mahammedi H, Tantot F, Jamet A, Escudier B, Flippot R, Albigès L. **Eur Urol.** 2021 ep;80(3):325-329. doi: 10.1016/j.eururo.2021.05.020. Epub 2021 Jun 5.

Nivoren (**GETUG AFU 26**) : Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougouin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S. **Clin Cancer Res.** 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18.

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (**GETUG-AFU V05**) Trial. Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard JC, Huillard O, Rolland F, Houédé N, Spano JP, Demery ME, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C; VESPER Trial Investigators. **Clin Genitourin Cancer.** 2021 Dec;19(6):554-562. doi: 10.1016/j.clgc.2021.08.005. Epub 2021 Sep 8. PMID: 34602349

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The **CABADOC Trial**. Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K; Groupe d'Etude des Tumeurs Uro-Genitales (GETUG). **Eur Urol.** 2021 Nov 14;S0302-2838(21)02117-5. doi: 10.1016/j.eururo.2021.10.016. Online ahead of print. PMID: 34789394

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the **GETUG group** (Groupe d'Etude des Tumeurs Uro-Genitales). Cancel M, Fromont G, Blonz C, Chevreaux C, Rioux-Leclercq N, Laguerre B, Oudard S, Gross-Goupil M, Gravis G, Goldwasser F, Rolland F, Delva R, Moise L, Emambux S, Vassal C, Zanetta S, Penel N, Fléchon A, Barthélémy P, Saldana C, Lefort F, Escudier B, Linassier C, Albiges L. **Eur J Cancer.** 2021 Oct 4;158:1-11. doi: 10.1016/j.ejca.2021.08.046. Online ahead of print. PMID: 34619467

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer **GETUG/AFU 19 Study**. Culine S, Fléchon A, Gravis G, Roubaud G, Lorient Y, Joly F, Barthélémy P, Assaf E, Mahammed H, Beuzeboc P, Houédé N, Rolland F, Guillot A, Gross-Goupil M, Spano JP, Tartas S, Deblock M, Chevreaux C, Serrate C, Manduzio H, Habibian M, Thézénas S, Allory Y. **Clin Genitourin Cancer.** 2021 Aug;19(4):e216-e222. doi: 10.1016/j.clgc.2021.02.005. Epub 2021 Feb 24. PMID: 33753043

Nivoren (**GETUG AFU 26**) : Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. Billon E, Chanez B, Rochigneux P, Albiges L, Vicier C, Pignot G, Walz J, Chretien AS, Gravis G, Olive D. **Front Immunol.** 2021 Apr 20;12:670827. doi: 10.3389/fimmu.2021.670827. eCollection 2021. PMID: 33959132